- COMMENT
Targeted protein degraders: a call for collective action to advance safety assessment
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Nature Reviews Drug Discovery 21, 401-402 (2022)
doi: https://doi.org/10.1038/d41573-022-00055-9
Acknowledgements
This work was supported by the Health and Environmental Science Institute (HESI). The authors gratefully acknowledge the contributions of all speakers and the input from workshop participants of all sectors and geographical areas for enriching the discussions.
References
Chamberlain, P. P. & Hamann, L.G. Development of targeted protein degradation therapeutics. Nat. Chem. Biol. 15, 937–944 (2019).
Bekes, M., Langley, D. R. & Crews, C. M. PROTAC targeted protein degraders: the past is prologue. Nat. Rev. Drug Discov. 21, 181–200 (2022).
Moreau, K. et al. Proteolysis-targeting chimeras in drug development: a safety perspective. Br. J. Pharmacol. 177, 1709–1718 (2020).
Donovan, K. A. et al. Mapping the degradable kinome provides a resource for expedited degrader development. Cell 183, 1714–1731.e10 (2020).
Nowak, R. & Jones, L, H. Target validation using PROTACs: applying the four pillars framework. SLAS Discov. 26, 474–483 (2021).
Supplementary Information
Competing Interests
HESI does not have a direct conflict of interest and holds no financial stake in specific pharmaceutical products or methods. The HESI scientific programming described in this article was supported by in-kind contributions from public and private sector participants of time, expertise and experimental effort, and direct funding from multiple pharmaceutical companies. A list of supporting organizations is available at www.hesiglobal.org. L.H.J. serves on the scientific advisory board for, and holds equity in, Interline Therapeutics, Umbra Therapeutics and Rapafusyn Pharmaceuticals. He also holds equity in Jnana Therapeutics and consults for EoCys. The Center for Protein Degradation at DFCI receives research funding from Deerfield. L.L., M.P., M.R, R.R., K.S., L.V. and M.B.W. are employed by companies engaged in the TPD field as indicated in their affiliations.